Alkaptonuria, or “black urine disease”, is a very rare inherited disorder that prevents the body from fully breaking down two protein building blocks (amino acids) called tyrosine and phenylalanine. It is a rare disorder of autosomal recessive inheritance. It is caused by a mutation in a gene that results in the accumulation of homogentisic acid (HGA). Characteristically, the excess HGA means sufferers pass dark urine, which upon standing turns black. This is a feature present from birth. Overtime patients develop other manifestations of AKU, due to deposition of HGA in collagenous tissues, namely ochronosis and ochronotic osteoarthropathy.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/alkaptonuria-market
The Alkaptonuria market report also covers emerging drugs, current treatment practices, Alkaptonuria market share of the individual therapies, current and forecasted Alkaptonuria Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Alkaptonuria treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Alkaptonuria Market Key Facts
-
As per the US National Library of Medicine, alkaptonuria is rare, affecting 1 in 250,000 to 1 million people worldwide. Alkaptonuria is more common in certain areas of Slovakia and in the Dominican Republic.
-
According to the study carried out by Ranganath et al. titled “Identification of alkaptonuria in the general population: a United Kingdom experience describing the challenges, possible solutions and persistent barriers” showed that very few patients were identified worldwide including newly identified non-UK people with AKU. The assumed prevalence in the UK, as in most parts of the world, is between 1 in 250,000 and 1 in 1,000,000.
-
As per the article by Gil et al. titled “Orthopedic Manifestations of Ochronosis: Pathophysiology, Presentation, Diagnosis, and Management” alkaptonuria has an estimated prevalence ranging from 1:200,000 to 1:1,000,000 live births worldwide.
-
As per the article by Mistry et al. titled “Alkaptonuria” showed that the worldwide prevalence of AKU is 1 case in 250,000–1 000,000 births.
Key Benefits of Alkaptonuria Market Report
-
Alkaptonuria market report provides an in-depth analysis of Alkaptonuria Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Alkaptonuria market report will help in developing business strategies by understanding the Alkaptonuria Market trends & developments, key players, and future market competition that will shape and drive the Alkaptonuria market in the upcoming years.
-
The Alkaptonuria market report covers Alkaptonuria’s current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Alkaptonuria market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The increase in the patient pool in the 7MM and the expected entry of emerging therapy such as Nitisinone is expected to boost the Alkaptonuria (AKU) market in the coming year.
The Alkaptonuria market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Alkaptonuria market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Alkaptonuria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Alkaptonuria Epidemiology
The Alkaptonuria epidemiology section covers insights about the historical and current Alkaptonuria patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Alkaptonuria Epidemiology Segmentation –
-
Total Prevalent Cases
-
Diagnosed and Treatable Cases
Alkaptonuria Drugs Uptake and Key Market Players
The Alkaptonuria Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alkaptonuria market or expected to get launched in the market during the study period. The analysis covers Alkaptonuria market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
At present, the Swedish Orphan Biovitrum (SOBI) is developing nitisinone for the treatment of Alkaptonuria (AKU). Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. Nitisinone is expected to enter the market during the forecasted period.
Table of Content
1. Key Insights
2. Executive Summary
3. Alkaptonuria Competitive Intelligence Analysis
4. Alkaptonuria Market Overview at a Glance
5. Alkaptonuria Disease Background and Overview
6. Alkaptonuria Patient Journey
7. Alkaptonuria Epidemiology and Patient Population
8. Alkaptonuria Treatment Algorithm, Current Treatment, and Medical Practices
9. Alkaptonuria Unmet Needs
10. Key Endpoints of Alkaptonuria Treatment
11. Alkaptonuria Marketed Products
12. Alkaptonuria Emerging Therapies
13. Alkaptonuria Seven Major Market Analysis
14. Attribute Analysis
15. Alkaptonuria Market Outlook (7 major markets)
16. Alkaptonuria Access and Reimbursement Overview
17. KOL Views on the Alkaptonuria Market.
18. Alkaptonuria Market Drivers
19. Alkaptonuria Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/alkaptonuria-market
Latest Healthcare Blog By DelveInsight –
Hereditary Deafness Market | Hearing Loss Market
As per Delveinsight’s analysis, it is estimated that the maximum number of people that are suffering from hereditary loss chose the option of hearing aids, as they are much affordable and accessible, and there is no such requirement of undergoing surgery. In the coming years, the improvements in the cochlear implant, and the introduction of artificial intelligence in hearing aids are expected to drive the Hereditary Deafness market. The key companies in the Hereditary Deafness Market include Oticon Medical, Audina Hearing Instruments, Phonak, Decibel Therapeutics, Pipeline Therapeutics, Rion, and others. To get a more detailed analysis on the Hereditary Deafness Devices Market, visit: Hereditary Deafness Devices Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/